Exagamglogene autotemcel for beta-thalassemia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 23 Dec 2019: Trial registered, NCT04208529
  2. 20 Jan 2021: Trial started, NCT04208529
  3. 28 Jul 2022: Trial registered, NCT05477563
  4. 2 Aug 2022: Trial started, NCT05477563

The trials

NCT05477563: Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

State
Under way
Phase
Phase 3
People
26 planned
Started
2 Aug 2022
Primary completion
9 Jun 2027
Arms
CTX001
Results
None posted
  1. 28 Jul 2022: Trial registered
  2. 2 Aug 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Exa-cel.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.